Pfizer Completes Acquisition of Vicuron Pharmaceuticals
16-Sep-2005
Through the transaction, Pfizer has acquired two new product candidates currently under review at the U.S. Food and Drug Administration (FDA): anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The addition of these product candidates broadens Pfizer's presence in anti-infectives where the company has a long history of providing patients and physicians with life-saving medicines.
Organizations
Pfizer
Vicuron Pharmaceuticals
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.